Market Size of Epilepsy Drugs Industry
Study Period | 2018 - 2028 |
Market Size (2024) | USD 9.51 Billion |
Market Size (2029) | USD 11.96 Billion |
CAGR (2024 - 2029) | 4.69 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Epilepsy Drugs Market Analysis
The Epilepsy Drugs Market size is estimated at USD 9.51 billion in 2024, and is expected to reach USD 11.96 billion by 2029, growing at a CAGR of 5% during the forecast period (2024-2029).
The epilepsy drug market is driven by the rising prevalence of epilepsy globally, which contributes to a growing patient population, creating a higher demand for epilepsy-related medications and treatments. Moreover, ongoing research and development have led to the discovery of new and more effective anti-epileptic drugs and therapies, expanding the treatment options available.
The growing burden of epilepsy is expected to create the demand for effective anti-epileptic drugs, which is likely to contribute to market growth over the forecast period. For instance, according to the World Health Organization's February 2023 report, epilepsy affected approximately 50 million people globally, making it one of the most prevalent neurological disorders worldwide. Similarly, according to GOV.UK data published in January 2024, a total of 191,623 drug seizures occurred in England and Wales in the year ending March 2023, a 1% increase compared to the previous year (188,929). Such a high burden of epilepsy creates the need for treatment and, thus, drives the market's growth.
Furthermore, supportive policies, research grants, and government initiatives aimed at epilepsy awareness, research, and treatment can stimulate growth in the epilepsy market. For instance, in November 2023, the Epilepsy Foundation launched a public awareness campaign called 'Change Epilepsy Story' aimed at combating the stigma surrounding epilepsy. By encouraging people with epilepsy and their caregivers to share their experiences, including diagnosis and treatment, the campaign hopes to raise awareness and promote understanding. This type of initiative is expected to fuel growth in the epilepsy market.
Additionally, the increasing launch of drugs for the treatment of epilepsy by market players at affordable prices is also contributing to the growth of the market. For instance, in October 2023, Catalyst Pharmaceuticals Inc. announced that it had participated in the 11th Annual Epilepsy Awareness Day & Education Expo to raise awareness and education among the epilepsy community in partnership with Sofie's Journey and Epilepsy Alliance of America, which hosted the largest gathering of patients, families, and physicians in the United States. Such initiatives are expected to create awareness of epilepsy, thereby boosting market growth.
Thus, owing to the abovementioned factors, the market's growth is expected to accelerate over the coming years. However, side effects associated with drugs and the recent expiration of patents on major drugs may impede the market's growth.
Epilepsy Drugs Industry Segmentation
As per the scope of this report, epilepsy is a central nervous system (neurological) disorder when brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of awareness. Epilepsy drugs do not cure epilepsy but help to control seizures.
The epilepsy drugs market is segmented by drugs, distribution channels, and geography. By drugs, the market is segmented as first-generation anti-epileptics, second-generation anti-epileptics, and third-generation anti-epileptics. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and other distribution channels. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East And Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD) for the above segments.
By Drugs | |
First Generation Anti-epileptics | |
Second Generation Anti-epileptics | |
Third Generation Anti-epileptics |
By Distribution Channel | |
Hospital Pharmacy | |
Retail Pharmacies | |
Other Distribution Channels |
By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Epilepsy Drugs Market Size Summary
The epilepsy drugs market is poised for growth, driven by a combination of new drug approvals and the increasing prevalence of epilepsy worldwide. The market experienced initial setbacks due to the COVID-19 pandemic, which disrupted neurology activities and hindered access to medications and healthcare professionals. However, the approval of new treatments, such as GW Pharmaceuticals' cannabidiol for tuberous sclerosis complex, is expected to propel market growth. The demand for epilepsy drugs is further fueled by the high global burden of the disease, with a significant portion of the affected population residing in low and middle-income countries. The introduction of affordable anti-epileptic drugs by companies like Alkem Laboratories and Sun Pharmaceutical Industries is also contributing to market expansion. Additionally, rising awareness campaigns and strategic alliances are anticipated to further stimulate market growth.
The market is characterized by the dominance of second-generation anti-epileptic drugs, which offer benefits such as reduced drug-drug interactions and fewer adverse effects. The launch of new drugs and the expansion of product portfolios through acquisitions, such as UCB's acquisition of Zogenix, are key strategies employed by major players to enhance their market presence. The North American region is expected to witness significant growth due to the high prevalence of epilepsy and the strategic initiatives undertaken by market players. The approval of drugs for various age groups, including pediatric patients, and ongoing research collaborations are expected to drive market growth in the region. The market remains consolidated, with major players like Abbott Laboratories, GlaxoSmithKline, and Pfizer focusing on new product development and strategic mergers and acquisitions to increase their market share.
Epilepsy Drugs Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rise in the New Drug Approvals over the Past Few Years
-
1.2.2 Increase in the Cases of Epilepsy
-
-
1.3 Market Restraints
-
1.3.1 Side Effects Associated With the Drugs
-
1.3.2 Recent Patent Expiration of Major Brands
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD)
-
2.1 By Drugs
-
2.1.1 First Generation Anti-epileptics
-
2.1.2 Second Generation Anti-epileptics
-
2.1.3 Third Generation Anti-epileptics
-
-
2.2 By Distribution Channel
-
2.2.1 Hospital Pharmacy
-
2.2.2 Retail Pharmacies
-
2.2.3 Other Distribution Channels
-
-
2.3 By Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Epilepsy Drugs Market Size FAQs
How big is the Epilepsy Drugs Market?
The Epilepsy Drugs Market size is expected to reach USD 9.51 billion in 2024 and grow at a CAGR of 4.69% to reach USD 11.96 billion by 2029.
What is the current Epilepsy Drugs Market size?
In 2024, the Epilepsy Drugs Market size is expected to reach USD 9.51 billion.